Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | acetylcholinesterase | 0.0217 | 0.7166 | 1 |
Mycobacterium tuberculosis | Carboxylesterase LipT | 0.0037 | 0 | 0.5 |
Echinococcus granulosus | carboxylesterase 5A | 0.0217 | 0.7166 | 1 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0253 | 0.8609 | 1 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0037 | 0 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.0217 | 0.7166 | 0.8323 |
Loa Loa (eye worm) | hypothetical protein | 0.0217 | 0.7166 | 0.8323 |
Loa Loa (eye worm) | carboxylesterase | 0.0217 | 0.7166 | 0.8323 |
Echinococcus multilocularis | geminin | 0.0206 | 0.6739 | 0.9404 |
Echinococcus multilocularis | acetylcholinesterase | 0.0217 | 0.7166 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0206 | 0.6739 | 0.9404 |
Trichomonas vaginalis | set domain proteins, putative | 0.0288 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0217 | 0.7166 | 0.8323 |
Mycobacterium ulcerans | carboxylesterase, LipT | 0.0037 | 0 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0217 | 0.7166 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0217 | 0.7166 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0206 | 0.6739 | 0.9404 |
Echinococcus granulosus | geminin | 0.0206 | 0.6739 | 0.9404 |
Brugia malayi | Pre-SET motif family protein | 0.0253 | 0.8609 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.0217 | 0.7166 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0217 | 0.7166 | 0.8323 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0217 | 0.7166 | 1 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0037 | 0 | 0.5 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0217 | 0.7166 | 0.8323 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -5.12 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.825 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.764 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.76 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.748 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.718 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.685 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.662 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.635 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.